Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
about
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survivalProgrammed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancerA Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune CheckpointsContemporary Treatment of Metastatic Renal Cell CarcinomaCancer immunotherapy: the beginning of the end of cancer?PD-1/PD-L1 blockade in cancer treatment: perspectives and issuesPredictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysisClinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysisA Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All CancersImmunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigationsNivolumab in the treatment of malignant melanoma: review of the literatureImmunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesSubverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancerPD-1 as an emerging therapeutic target in renal cell carcinoma: current evidenceImmunotherapy for primary brain tumors: no longer a matter of privilegeThe blockade of immune checkpoints in cancer immunotherapyThe PD1:PD-L1/2 Pathway from Discovery to Clinical ImplementationNivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experiencePD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsAnti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potentialThe Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaMHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancersA fiber-modified adenoviral vector interacts with immunoevasion molecules of the B7 family at the surface of murine leukemia cells derived from dormant tumorsLoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaColocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escapePD-L1 regulates the development, maintenance, and function of induced regulatory T cellsPD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma.FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection.Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies.PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressivenessAt the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancerB7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.Inhibitors of B7-CD28 costimulation in urologic malignancies.Programmed cell death ligand 1 expression in osteosarcoma.Novel immunotherapy in metastatic renal cell carcinoma.Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
P2860
Q24550945-B360FF53-228A-4ED4-BCD5-FDA26236C653Q24685406-181A89A5-D24A-494B-B3C3-5D175564BF06Q26738729-0B44DAD1-546D-4298-9545-2DF1C25CBF43Q26740594-01EF738B-2459-4D5A-A6DC-8237F7FADB2BQ26752277-31DAEE61-8D44-4A51-8D30-DCE6BFA06952Q26768641-6EDE9B76-5899-4AB5-9E91-28DC7E9FCA56Q26769728-1E307975-E547-4FA4-97FC-0846DA465C91Q26775460-437AA2B9-9FD4-437A-BA3A-E6900E74D0C0Q26777111-ED4AEC09-60BF-4981-A366-CF0982A00F98Q26781038-F5D44D07-0910-4DF5-9DBA-DA85ABBFBD9FQ26798330-05DFA8AF-4850-457B-8FC6-FD33E07D180EQ26798402-2E46E4AC-8E13-4713-9E4B-0EC375AA2B8EQ26852704-0E081C4A-8FBF-49A3-A84C-39B84A61B9BCQ26865789-D0CBBCC7-7DA6-4E98-A501-2CBC50DB82F2Q27002510-7363DD48-1A54-4980-9FC9-1EDEF12500B6Q27860852-76EA0BD6-8AF6-471F-B0F4-19984E071332Q28066941-FA13F3AB-9066-492A-A20E-A3194CB34C44Q28068959-79A2EBC7-8A8D-4DF1-B6C7-6AAC5EFB7451Q28075712-7A9266B5-7B79-438A-8597-C1B373E46B25Q28084942-511CD27C-9282-4DEF-9B11-0407C39B299EQ28088496-AAC1104B-2374-4CB7-A81A-F756E86846C7Q28306431-2F1335DA-A9F5-4164-AB43-440008BB300BQ28510246-CF2D8B33-A19B-4C52-B3BA-69E4430AD164Q29620812-22B86AD4-48A7-4FB8-AC8F-AD65D8DC5AD0Q29620881-6C95C950-1CB3-4779-98BD-043539C061E5Q30080038-E612A80A-CECD-4066-A368-259A8EE9ECD2Q30275174-B2A332D4-19CD-488A-A835-288198D230B0Q33275611-05608513-5A5D-4701-A201-83831A1211EFQ33320890-E3C927D5-3ED3-4C72-A01B-33A6357F44DBQ33605673-B13512C5-461F-4749-A77B-13E1725B6AA4Q33606111-5FCA4150-A6FB-4C46-B3E1-225A25491657Q33636256-428B197D-7751-410B-9154-B869EED6EF9AQ33704636-90BEBA06-D27C-481E-9A51-294A31988CD7Q33732329-F88309EC-D13E-48E2-AEB5-02A07A8A426EQ33738756-B2B2BED4-AD64-4416-BC98-D0E8A0645C6BQ33759287-923E8E4F-ED88-46DD-A424-171821F3E60DQ33827752-A710B4D3-5450-49CA-839F-644741E95F3AQ33848154-3432B53E-D278-4D6D-97F2-279F15D4F07FQ33863074-E88141B3-67A9-46B6-AC2B-8C057808F2C1Q33894390-BE81880B-1E6E-4DDA-BD8D-05649A35F1C9
P2860
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Costimulatory B7-H1 in renal c ...... d potential therapeutic target
@ast
Costimulatory B7-H1 in renal c ...... d potential therapeutic target
@en
Costimulatory B7-H1 in renal c ...... d potential therapeutic target
@nl
type
label
Costimulatory B7-H1 in renal c ...... d potential therapeutic target
@ast
Costimulatory B7-H1 in renal c ...... d potential therapeutic target
@en
Costimulatory B7-H1 in renal c ...... d potential therapeutic target
@nl
prefLabel
Costimulatory B7-H1 in renal c ...... d potential therapeutic target
@ast
Costimulatory B7-H1 in renal c ...... d potential therapeutic target
@en
Costimulatory B7-H1 in renal c ...... d potential therapeutic target
@nl
P2093
P2860
P3181
P356
P1476
Costimulatory B7-H1 in renal c ...... d potential therapeutic target
@en
P2093
Bradley C Leibovich
Christine M Lohse
Eugene D Kwon
Horst Zincke
John C Cheville
John R Lobo
Kent G Krejci
Lieping Chen
Michael D Gillett
Michael L Blute
P2860
P304
17174-17179
P3181
P356
10.1073/PNAS.0406351101
P407
P577
2004-11-29T00:00:00Z